Condition 1: Trigeminal Neuralgia. Condition 2: Chronic Migraine. Trigeminal neuralgia Chronic migraine without aura
Conditions
Interventions
Intervention 1: Intervention group 1: First two weeks of placebo and then eight weeks of low-dose naltrexalone (4.5 mg) will be given. In the low-dose placebo and naltrexalone phases, the capsules are
Sponsors
Kerman University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: According to ICHD3 criteria, they are diagnosed with TN or chronic headache. Be over 18 years old Have the necessary cooperation to participate in the study.
Exclusion criteria
Exclusion criteria: Patient non-cooperation The patient is pregnant or breastfeeding. If the patient uses opioid analgesics or inhales opioids If the patient regularly uses anti-inflammatory drugs. Known allergy or reaction to naltrexone If the patient consumes alcohol and can not refrain from consuming it during the study. The patient has rheumatic or autoimmune diseases The patient has been diagnosed with a mental illness that disrupts his or her collaboration in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Low-dose naltrexone, chronic migraine, trigeminal neuralgia. Timepoint: Before the intervention and every day during the intervention. Method of measurement: VAS questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHoma Kamyabi
Kerman University of Medical Sciences
Outcome results
None listed